Bionexus Gene Lab Corp Share Price: BGLC (Bionexus Gene Lab Corp) Stock Price Today & Updates | INDmoney

Question 1

What is Bionexus Gene Lab Corp share price today?

Accepted Answer

Bionexus Gene Lab Corp (BGLC) share price today is {{live_price}}.

Question 2

Can Indians buy Bionexus Gene Lab Corp shares?

Accepted Answer

Yes, Indians can invest in the Bionexus Gene Lab Corp (BGLC) from India.

With INDmoney, you can buy Bionexus Gene Lab Corp at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Bionexus Gene Lab Corp at zero transaction cost.

Question 3

How can I buy Bionexus Gene Lab Corp shares from India?

Accepted Answer

It is very easy to buy Bionexus Gene Lab Corp from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Question 4

Can Fractional shares of Bionexus Gene Lab Corp be purchased?

Accepted Answer

Yes, you can buy fractional shares of Bionexus Gene Lab Corp with INDmoney app.

Question 5

What are the documents required to start investing in Bionexus Gene Lab Corp stocks?

Accepted Answer

To start investing in Bionexus Gene Lab Corp, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

Question 6

What are today’s High and Low prices of Bionexus Gene Lab Corp

Accepted Answer

Today’s highest price of Bionexus Gene Lab Corp (BGLC) is {{1_rba_end}}.

Today’s lowest price of Bionexus Gene Lab Corp (BGLC) is {{1_rba_st}}.

Question 7

What is today's market capitalisation of Bionexus Gene Lab Corp

Accepted Answer

Today's market capitalisation of Bionexus Gene Lab Corp BGLC is 7.6M

Question 8

What is the 52 Week High and Low Range of Bionexus Gene Lab Corp

Accepted Answer

52 Week High
{{rba_end}}
52 Week Low
{{rba_st}}

Question 9

How much percentage Bionexus Gene Lab Corp is down from its 52 Week High?

Accepted Answer

Bionexus Gene Lab Corp (BGLC) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

Question 10

How much percentage Bionexus Gene Lab Corp is up from its 52 Week low?

Accepted Answer

Bionexus Gene Lab Corp (BGLC) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

Question 11

What are the historical returns of Bionexus Gene Lab Corp?

Accepted Answer

1 Month Returns
{{1mr}}%
3 Months Returns
{{3mr}}%
1 Year Returns
{{1yr}}%
5 Years Returns
{{5yr}}%

Question 12

Who is the Chief Executive Officer (CEO) of Bionexus Gene Lab Corp

Accepted Answer

Mr. Su-Leng  Tan is the current Chief Executive Officer (CEO) of Bionexus Gene Lab Corp.

Period	Bionexus Gene Lab Corp	Index (Russel 2000)
3 Months	-26.21%	0.0%
6 Months	-46.86%	0.0%
1 Year	-60.59%	0.0%
3 Years	-98.32%	-22.3%

Market Capitalization	7.6M
Book Value	$0.54
Earnings Per Share (EPS)	-0.15

Profit Margin	-24.01%
Operating Margin TTM	13.13%

Return On Assets TTM	-10.11%
Return On Equity TTM	-28.44%

Revenue TTM	9.2M
Revenue Per Share TTM	0.53
Quarterly Revenue Growth YOY	-23.1%
Gross Profit TTM	2.2M
EBITDA	-1.5M
Diluted Eps TTM	-0.15
Quarterly Earnings Growth YOY	-0.95

Bionexus Gene Lab Corp (BGLC)

Performance

Returns

Highlights

Analyst Recommendation

Company Financials

Technicals Summary

Peers

Decreasing Revenue

Increasing Net Profit

Vs ECL

Company Information

Discover More

FAQs

EPS Estimate Current Year	0.0
EPS Estimate Next Year	0.0
EPS Estimate Current Quarter	0.0
EPS Estimate Next Quarter	0.0

	FY19	Y/Y Change
Revenue	127.0K	↓ 40.21%
Net Income	-246.5K	↓ 1031.69%
Net Profit Margin	-194.14%	↓ 206.6%

	FY20	Y/Y Change
Revenue	11.4M	↑ 8872.03%
Net Income	1.1M	↓ 543.91%
Net Profit Margin	9.61%	↑ 203.75%

	FY21	Y/Y Change
Revenue	13.4M	↑ 17.31%
Net Income	751.6K	↓ 31.31%
Net Profit Margin	5.62%	↓ 3.99%

	FY22	Y/Y Change
Revenue	10.9M	↓ 18.21%
Net Income	-356.0K	↓ 147.36%
Net Profit Margin	-3.26%	↓ 8.88%

	FY23	Y/Y Change
Revenue	9.8M	↓ 10.6%
Net Income	-2.6M	↑ 638.57%
Net Profit Margin	-26.91%	↓ 23.65%

	Q1 FY23	Q/Q Change
Revenue	2.4M	↓ 16.28%
Net Income	-69.1K	↓ 56.0%
Net Profit Margin	-2.91%	↑ 2.62%

	Q2 FY23	Q/Q Change
Revenue	2.6M	↑ 7.98%
Net Income	-259.3K	↑ 275.37%
Net Profit Margin	-10.1%	↓ 7.19%

	Q3 FY23	Q/Q Change
Revenue	2.6M	↓ 0.51%
Net Income	-2.6M	↑ 906.03%
Net Profit Margin	-102.13%	↓ 92.03%

	Q4 FY23	Q/Q Change
Revenue	2.3M	↓ 10.99%
Net Income	307.4K	↓ 111.79%
Net Profit Margin	13.52%	↑ 115.65%

	FY18	Y/Y Change
Total Assets	1.7M	-
Total Liabilities	130.3K	-

	FY19	Y/Y Change
Total Assets	1.2M	↓ 25.48%
Total Liabilities	108.9K	↓ 16.45%

	FY20	Y/Y Change
Total Assets	10.1M	↑ 721.56%
Total Liabilities	3.5M	↑ 3071.74%

	FY22	Y/Y Change
Total Assets	8.7M	↓ 8.71%
Total Liabilities	2.1M	↓ 13.34%

	Q1 FY24	Q/Q Change
Revenue	2.4M	↑ 4.79%
Net Income	-103.8K	↓ 133.75%
Net Profit Margin	-4.36%	↓ 17.88%

	Q2 FY24	Q/Q Change
Revenue	2.0M	↓ 17.1%
Net Income	199.1K	↓ 291.89%
Net Profit Margin	10.08%	↑ 14.44%

	FY18	Y/Y Change
Operating Cash Flow	-274.1K	↓ 176.73%
Investing Cash Flow	-51.7K	↓ 99.03%
Financing Cash Flow	742.9K	↓ 87.15%

	FY19	Y/Y Change
Operating Cash Flow	-217.3K	↓ 20.73%
Investing Cash Flow	-12.8K	↓ 75.21%
Financing Cash Flow	-180.8K	↓ 124.34%

	FY20	Y/Y Change
Operating Cash Flow	552.7K	↓ 354.37%
Investing Cash Flow	1.3M	↓ 10398.74%
Financing Cash Flow	-4.9K	↓ 97.26%

	FY21	Y/Y Change
Operating Cash Flow	9.2K	↓ 98.34%
Investing Cash Flow	-490.6K	↓ 137.16%
Financing Cash Flow	-28.2K	↑ 470.49%

	Q1 FY23	Q/Q Change
Operating Cash Flow	-118.3K	↓ 124.93%
Investing Cash Flow	-5.1K	↑ 65.34%
Financing Cash Flow	-8.7K	↓ 7243433.33%

	Q2 FY23	Q/Q Change
Operating Cash Flow	-22.0K	↓ 81.37%
Investing Cash Flow	-3.1K	↓ 39.52%
Financing Cash Flow	-4.2K	↓ 51.54%

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Bionexus Gene Lab Corp	-5.99%	-46.86%	-60.59%	-98.32%	-98.32%
Air Products & Chemicals Inc.	-3.15%	9.6%	-8.01%	0.6%	24.2%
Linde Plc	3.39%	-1.81%	18.17%	44.74%	146.67%
Dupont De Nemours Inc	2.49%	11.17%	4.74%	10.81%	12.24%
Sherwin-williams Company, The	6.22%	4.69%	33.07%	19.15%	106.97%
Ecolab Inc.	5.83%	9.12%	34.88%	7.89%	22.05%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Bionexus Gene Lab Corp	NA	NA	NA	0.0	-0.28	-0.1	NA	0.54
Air Products & Chemicals Inc.	23.76	23.76	1.46	12.34	0.16	0.05	0.03	67.93
Linde Plc	34.85	34.85	2.57	15.53	0.16	0.07	0.01	79.96
Dupont De Nemours Inc	104.13	104.13	0.45	3.77	0.01	0.03	0.02	55.9
Sherwin-williams Company, The	36.63	36.63	3.99	11.49	0.68	0.1	0.01	14.95
Ecolab Inc.	41.32	41.32	2.38	6.62	0.22	0.07	0.01	23.46

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Bionexus Gene Lab Corp	NA	$7.6M	-98.32%	NA	-24.01%
Air Products & Chemicals Inc.	Buy	$60.8B	24.2%	23.76	21.24%
Linde Plc	Buy	$222.3B	146.67%	34.85	19.49%
Dupont De Nemours Inc	Buy	$34.0B	12.24%	104.13	5.51%
Sherwin-williams Company, The	Buy	$91.0B	106.97%	36.63	10.92%
Ecolab Inc.	Hold	$70.2B	22.05%	41.32	10.95%

Organization	Bionexus Gene Lab Corp
Employees	30
CEO	Mr. Su-Leng Tan
Industry	Commercial Services